Kurzfassung

The present challenge is to understand how the different EGFR1/HER2 and HER3 expression levels may co-express in individual tumors and to evaluate these markers for their means for response and outcome prediction.
 In this context, the phase III EXPAND study will provide excellent data on the role of the EGFR inhibitor Cetuximab versus a control group as well as, the correlation with the appearance of rash. Thus, within the curuent phase III study we wiil test tumor biopsies for...The present challenge is to understand how the different EGFR1/HER2 and HER3 expression levels may co-express in individual tumors and to evaluate these markers for their means for response and outcome prediction.
 In this context, the phase III EXPAND study will provide excellent data on the role of the EGFR inhibitor Cetuximab versus a control group as well as, the correlation with the appearance of rash. Thus, within the curuent phase III study we wiil test tumor biopsies for expression of HER3 and correlate that with the quantified IHC and FISH tests for EGFR1 (NSCLC scoring system) and HER2 (TOGA), which could help to further elucidate the link between the antitumor activity of cetuximab and the corresponding biomarkers.
Additionally, we will quantify the already performed staining for EGFR1 and HER2 by ACIS (Automated Cellular khagrng System, DAKO) to more profoundly compare the different protein expression levels with their corresponding FISH analyses.» weiterlesen» einklappen